All In Biotech

Investigational drug · Phase 3

Afimkibart

Also called: RO7790121, RVT-3101, PF 06480605

Not approved by FDA. In 12 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Moderately to Severely Active Ulcerative Colitis, Moderately to Severely Active Crohns Disease, Atopic Dermatitis.

Phase 3

Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

12

12 still active

All registered trials

13

Any phase or sponsor naming "Afimkibart"

First trial start

2023

Jul 24, 2023

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Afimkibart", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Moderately to Severely Active Ulcerative Colitis
  • Moderately to Severely Active Crohns Disease
  • Atopic Dermatitis
  • Rheumatoid Arthritis
  • Crohns Disease

Approved drugs for the same conditions: Rheumatoid arthritis · Atopic dermatitis (eczema) · Crohn's disease · Ulcerative colitis · Immunology and inflammation · Dermatology

Largest trials

Live from ClinicalTrials.gov: studies naming "Afimkibart" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 17 on PubMed

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Roche (Genentech).

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.